Renske Olie

Academic Staff

Dr Renske Olie studied Medicine at Maastricht University and obtained her MD in 2006. Subsequently, she specialised in Internal Medicine (specialisation vascular medicine) in Tilburg and Maastricht UMC+. Currently, she works as an internist at the Department of Internal Medicine and the Thrombosis Expertise Center (TEC) at the MUMC+ Heart+Vascular Center, where she started an outpatient clinic for high-risk patients on dual/triple antithrombotic therapy.

Since 2013, she has been involved in scientific research at CARIM. Her research focusses on the safety of antithrombotic strategies in high-risk patients with atherothrombotic disease, and the value of several laboratory tests in the risk assessment of these patients.

 

Department of Biochemistry
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht
Room number: 4.334
T: +31(0)43 387 50 05

  • 2024
  • 2023
    • Heuts, S., Ceulemans, A., Kuiper, G. J. A. J. M., Schreiber, J. U., van Varik, B. J., Olie, R. H., Ten Cate, H., Maessen, J. G., Milojevic, M., & Maesen, B. (2023). Optimal management of cardiac surgery patients using direct oral anticoagulants: recommendations for clinical practice. European Journal of Cardio-Thoracic Surgery, 64(4), Article ezad340. https://doi.org/10.1093/ejcts/ezad340
    • Schultinge, L., Hulshof, A. M., van Neerven, D., Mulder, M. M. G., Sels, J. W. E. M., Hulsewe, H. P. M. G., Kuiper, G. J. A. J. M., Olie, R. H., ten Cate, H., van der Horst, I. C. C., van Bussel, B. C. T., & Henskens, Y. M. C. (2023). Applications of rotational thromboelastometry in heparin monitoring in critical COVID-19 disease: Observations in the Maastricht Intensive Care COVID cohort. Thrombosis Update, 12(1), Article 100140. https://doi.org/10.1016/j.tru.2023.100140
  • 2022
    • Bor, W. L., de Veer, A. J. W., Olie, R. H., Rikken, S. A. O. F., Chan Pin Yin, D. R. P. P., Herrman, J. P. R., Vrolix, M., Meuwissen, M., Vandendriessche, T., van Mieghem, C., Magro, M., Bennaghmouch, N., Hermanides, R., Adriaenssens, T., Dewilde, W. J. M., & Ten Berg, J. M. (2022). Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study. Eurointervention, 18(4), e303-e313. https://doi.org/10.4244/eij-d-21-00703
  • 2021
    • Hulshof, A.-M., Olie, R. H., Vries, M. J. A., Verhezen, P. W. M., van der Meijden, P. E. J., Ten Cate, H., & Henskens, Y. M. C. (2021). Rotational Thromboelastometry in High-Risk Patients on Dual Antithrombotic Therapy After Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine, 8, Article 788137. https://doi.org/10.3389/fcvm.2021.788137
    • Olie, R. H., van der Meijden, P. E. J., Vries, M. J. A., Veenstra, L., van't Hof, A. W. J., ten Berg, J. M., Henskens, Y. M. C., & ten Cate, H. (2021). Antithrombotic therapy in high-risk patients after percutaneous coronary intervention; study design, cohort profile and incidence of adverse events. Netherlands Heart Journal, 29(10), 525-535. https://doi.org/10.1007/s12471-021-01606-2
    • Slikkerveer, M., van de Plas, A., Driessen, J. H. M., Wijngaard, R., de Vries, F., Olie, R., Meertens, N., & van den Bemt, P. (2021). Prescribing Errors With Low-Molecular-Weight Heparins. Journal of Patient Safety, 17(7), e587-e592. https://doi.org/10.1097/PTS.0000000000000417
    • Olie, R. H., Hensgens, R. R. K., Wijnen, P. A. H. M., Veenstra, L. F., de Greef, B. T. A., Vries, M. J. A., van der Meijden, P. E. J., ten Berg, J. M., ten Cate, H., Bekers, O., & Henskens, Y. M. C. (2021). Differential Impact of Cytochrome 2C19 Allelic Variants on Three Different Platelet Function Tests in Clopidogrel-Treated Patients. Journal of Clinical Medicine, 10(17), Article 3992. https://doi.org/10.3390/jcm10173992
    • Hulshof, A. M., Braeken, D. C. W., Ghossein-Doha, C., van Santen, S., Sels, J. W. E. M., Kuiper, G. J. A. J. M., van der Horst, I. C. C., ten Cate, H., van Bussel, B. C. T., Olie, R. H., & Henskens, Y. M. C. (2021). Hemostasis and fibrinolysis in COVID-19 survivors 6 months after intensive care unit discharge. Research and practice in thrombosis and haemostasis, 5(6), Article e12579. https://doi.org/10.1002/rth2.12579
    • de Breet, C. P. D. M., Zwaveling, S., Vries, M. J. A., van Oerle, R. G., Henskens, Y. M. C., Van't Hof, A. W. J., van der Meijden, P. E. J., Veenstra, L., ten Cate, H., & Olie, R. H. (2021). Thrombin Generation as a Method to Identify the Risk of Bleeding in High Clinical-Risk Patients Using Dual Antiplatelet Therapy. Frontiers in Cardiovascular Medicine, 8, Article 679934. https://doi.org/10.3389/fcvm.2021.679934
    • Mulder, M. M. G., Brandts, LI., Brüggemann, R. A. G., Koelmann, M., Streng, A. S., Olie, R. H., Gietema, H. A., Spronk, H. M. H., van der Horst, I. C. C., Sels, J.-W. E. M., Wildberger, J. E., van Kuijk, S. M. J., Schnabel, R. M., Ten Cate, H., Henskens, Y. M. C., & van Bussel, B. C. T. (2021). Serial markers of coagulation and inflammation and the occurrence of clinical pulmonary thromboembolism in mechanically ventilated patients with SARS-CoV-2 infection; the prospective Maastricht intensive care COVID cohort. Thrombosis Journal, 19(1), Article 35. https://doi.org/10.1186/s12959-021-00286-7
    • Hulshof, A. M., Vries, M., Verhezen, P., Wetzels, R., Haartmans, M., Olie, R., Ten Cate, H., & Henskens, Y. (2021). The Influence of Prostaglandin E1 and Use of Inhibitor Percentage on the Correlation between the Multiplate and VerifyNow in Patients on Dual Antiplatelet Therapy. Platelets, 32(4), 463-468. https://doi.org/10.1080/09537104.2020.1754378
    • Hulshof, A.-M., Brüggemann, R. A. G., Mulder, M. M. G., van de Berg, T. W., Sels, J.-W. E. M., Olie, R. H., Spaetgens, B., Streng, A. S., Verhezen, P., van der Horst, I. C. C., Ten Cate, H., Spronk, H. M. H., van Bussel, B. C. T., & Henskens, Y. M. C. (2021). Serial EXTEM, FIBTEM, and tPA Rotational Thromboelastometry Observations in the Maastricht Intensive Care COVID Cohort-Persistence of Hypercoagulability and Hypofibrinolysis Despite Anticoagulation. Frontiers in Cardiovascular Medicine, 8, Article 654174. https://doi.org/10.3389/fcvm.2021.654174
  • 2020
    • Bavalia, R., Abdoellakhan, R., Beenen, L. F., Brekelmans, M. P. A., Olie, R. H., ten Cate, H., Huisman, M., Kruip, M., Middeldorp, S., Meijer, K., Hutten, B. A., & Coppens, M. (2020). Outcome of intracranial bleeding managed with prothrombin complex concentrate in patients on direct factor Xa inhibitors or vitamin K antagonists. Thrombosis Research, 196, 404-409. https://doi.org/10.1016/j.thromres.2020.09.028
    • Streng, A. S., Delnoij, T. S. R., Mulder, M. M. G., Sels, J. W. E. M., Wetzels, R. J. H., Verhezen, P. W. M., Olie, R. H., Kooman, J. P., van Kuijk, S. M. J., Brandts, L., Ten Cate, H., Lorusso, R., van der Horst, I. C. C., van Bussel, B. C. T., & Henskens, Y. M. C. (2020). Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO. TH open : companion journal to thrombosis and haemostasis, 4(4), e365-e375. https://doi.org/10.1055/s-0040-1719083
    • Bavalia, R., Abdoellakhan, R., Brinkman, H. J. M., Brekelmans, M. P. A., Hamulyak, E. N., Zuurveld, M., Hutten, B. A., Westerweel, P. E., Olie, R. H., ten Cate, H., Kruip, M., Middeldorp, S., Meijer, K., & Coppens, M. (2020). Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate. Research and practice in thrombosis and haemostasis, 4(4), 569-581. https://doi.org/10.1002/rth2.12336
    • d'Alessandro, E., Becker, C., Bergmeier, W., Bode, C., Bourne, J. H., Brown, H., Buller, H. R., ten Cate-Hoek, A. J., ten Cate, V., van Cauteren, Y. J. M., Cheung, Y. F. H., Cleuren, A., Coenen, D., Crijns, H. J. G. M., de Simone, I., Dolleman, S. C., Klein, C. E., Fernandez, D. I., Granneman, L., ... Scientific Reviewer Committee (2020). Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. Thrombosis and Haemostasis, 120(4), 538-564. https://doi.org/10.1055/s-0040-1708035
  • 2019
    • Petersohn, S., Ramaekers, B. L. T., Olie, R. H., ten Cate-Hoek, A. J., Daemen, J.-W. H. C., ten Cate, H., & Joore, M. A. (2019). Comparison of three generic quality-of-life metrics in peripheral arterial disease patients undergoing conservative and invasive treatments. Quality of Life Research, 28(8), 2257-2279. https://doi.org/10.1007/s11136-019-02166-0
    • Olie, R. H., van der Meijden, P. E. J., Spronk, H. M. H., van Oerle, R., Barvik, S., Bonarjee, V. V. S., Ten Cate, H., & Nilsen, D. W. T. (2019). Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease. TH open : companion journal to thrombosis and haemostasis, 3(3), e259-e262. https://doi.org/10.1055/s-0039-1695710
  • 2018
    • ten Cate, H., Olie, R. H., ten Cate-Hoek, A. J., & Henskens, Y. M. C. (2018). Direct oral anticoagulants: When to consider laboratory testing?International Journal of Laboratory Hematology, 40(S1), 30-33. https://doi.org/10.1111/ijlh.12816
    • Olie, R. H., van der Meijden, P. E. J., & ten Cate, H. (2018). The coagulation system in atherothrombosis: Implications for new therapeutic strategies. Research and practice in thrombosis and haemostasis, 2(2), 188-198. https://doi.org/10.1002/rth2.12080
    • Spronk, H. M. H., Padro, T., Siland, J. E., Prochaska, J. H., Winters, J., van der Wal, A. C., Posthuma, J. J., Lowe, G., d'Alessandro, E., Wenzel, P., Coenen, D. M., Reitsma, P. H., Ruf, W., van Gorp, R. H., Koenen, R. R., Vajen, T., Alshaikh, N. A., Wolberg, A. S., Macrae, F. L., ... ten Cate, H. (2018). Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis. Thrombosis and Haemostasis, 118(2), 229-250. https://doi.org/10.1160/TH17-07-0492
    • Ten Cate, H., Olie, R. H., Ten Cate-Hoek, A. J., & Henskens, Y. M. C. (2018). Direkte orale Antikoagulanzien: Wann sollte ein Labortest erwogen werden?Vasomed, 30(5), 248-249. https://onlinelibrary.wiley.com/doi/10.1111/ijlh.12816
  • 2017
    • Olie, R. H., Meertens, N. E. L., Henskens, Y. M. C., & ten Cate, H. (2017). Empirically Reduced Dosages of Tinzaparin in Patients with Moderate-to-Severe Renal Insufficiency Lead to Inadequate Anti-Xa Levels. The Nephron Journals, 137(2), 113-123. https://doi.org/10.1159/000477474
    • Vries, M. J. A., Bouman, H. J., Olie, R. H., Veenstra, L. F., Zwaveling, S., Verhezen, P. W. M., ten Cate-Hoek, A. J., ten Cate, H., Henskens, Y. M. C., & van der Meijden, P. E. J. (2017). Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients. European Heart Journal-Cardiovascular Pharmacotherapy, 3(1), 11-17. https://doi.org/10.1093/ehjcvp/pvw026